Literature DB >> 15679717

Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics.

M Profita1, R Gagliardo, R Di Giorgi, F Pompeo, M Gjomarkaj, G Nicolini, J Bousquet, A M Vignola.   

Abstract

BACKGROUND: Several in vitro studies demonstrate that corticosteroids and long-acting beta(2) agonists may have a complementary and synergistic mode of action on the inflammatory processes in asthma.
METHODS: Sputum was induced in 20 mild to moderate asthmatic patients and the induced sputum cells (ISC) were cultured with beclomethasone dipropionate (BDP) 10(-7) M, salbutamol 10(-8) M and formoterol 10(-8) M either alone or in combination, BDP plus salbutamol and BDP plus formoterol, for 24 h. We measured the levels of growth macrophages-colony stimulating factor (GM-CSF), released on activation normal T cells expressed and activated (RANTES) and interleukin-8 (IL-8), in the supernatant of stimulated cells by ELISA. Furthermore, we assessed nuclear translocation of glucocorticoid receptor (GR) and the expression of beta(2) receptor in ISC by immunofluorescence and RT-PCR, respectively.
RESULTS: The release of GM-CSF, RANTES and IL-8 in ISC was significantly reduced by BDP plus salbutamol or formoterol as compared with either drug alone (P < 0.0001). beta(2) receptor expression was increased after 30 min of incubation with BDP and continued to increase over a time period of 4 h (P < 0.0001). Furthermore after 30 min of incubation, nuclear translocation of GR was greater with BDP plus salbutamol or formoterol than with any of the drugs alone (P < 0.0001).
CONCLUSION: The present ex vivo study demonstrates a complementary mode of action between BDP and salbutamol or formoterol leading to an enhanced anti-inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15679717     DOI: 10.1111/j.1398-9995.2005.00702.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  10 in total

Review 1.  Interactions between corticosteroids and beta2-agonists.

Authors:  Robert J Hancox
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 2.  A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.

Authors:  M A Giembycz; M Kaur; R Leigh; R Newton
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

3.  Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler.

Authors:  Sohita Dhillon; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  The long-acting β2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner.

Authors:  T Joshi; M Johnson; R Newton; M A Giembycz
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

5.  Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.

Authors:  Juan Carlos Cardet; Xiaofeng Jiang; Quan Lu; Norma Gerard; Kristen McIntire; Homer A Boushey; Mario Castro; Vernon M Chinchilli; Christopher D Codispoti; Anne-Marie Dyer; Fernando Holguin; Monica Kraft; Stephen Lazarus; Robert F Lemanske; Njira Lugogo; Dave Mauger; Wendy C Moore; James Moy; Victor E Ortega; Stephen P Peters; Lewis J Smith; Julian Solway; Christine A Sorkness; Kaharu Sumino; Michael E Wechsler; Sally Wenzel; Elliot Israel
Journal:  J Allergy Clin Immunol       Date:  2019-03-11       Impact factor: 10.793

Review 6.  Pharmacogenetics and the development of personalized approaches for combination therapy in asthma.

Authors:  Stacey M Miller; Victor E Ortega
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

7.  Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.

Authors:  Wilfried De Backer; Annick Devolder; Gianluigi Poli; Daniela Acerbi; Raffaella Monno; Christiane Herpich; Knut Sommerer; Thomas Meyer; Fabrizia Mariotti
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-06       Impact factor: 2.849

8.  Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.

Authors:  Luigino Calzetta; Maria Gabriella Matera; Francesco Facciolo; Mario Cazzola; Paola Rogliani
Journal:  Respir Res       Date:  2018-04-12

9.  Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations.

Authors:  Gabriele Nicolini; Nicola Scichilone; Andrea Bizzi; Alberto Papi; Leonardo M Fabbri
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

10.  Section 3. A discussion of flexible dosing and patient-centered therapy: highlights of the asthma summit 2009: beyond the guidelines.

Authors:  G Walter Canonica; Christopher Brightling
Journal:  World Allergy Organ J       Date:  2010-02-15       Impact factor: 4.084

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.